SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  For example, here is how to disable FireFox ad content blocking while on Silicon Investor.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
2735 95 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Regeneron (REGN) is a biotech working in recombinant DNA technology. Until '94 it generally traded between 10 and 20 dollars until the FDA beat it up on it's treatment for Lou Gehrig's Disease. While it was trading at the $4 level at the end of '94, the former chairman of Merck(I believe) took the helm and the stock climbed back to about 11, then traded between 11 and 14. In late May, Option volume increased, news about a discovery concerning muscles was announced, and the stock has risen sharply to Friday, May 24 '96 close of 18.875.

Historically, the stock has failed around 22. Yet AMGEN has more than a 17.7% stake with warrants to increase it's stake to 20%, at 16$ per share. Could this be the time it breaks out?
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2735Lucentis 2Q ex-US sale (from Novartis) were $536 m, more or less flat relative tMiljenko Zuanic-2 AM
2734Does short have a problem with ADVM? No at 13.5!Miljenko Zuanic-July 8
2733Saga over REGN future continue, and Medicare(CMS) part B is major obstacle. ObviMiljenko Zuanic-July 6
2732Due to its dermatology presence, and to *demoralized* Len self-fulfilling prophMiljenko Zuanic-July 2
2731REGN3500 (anti IL-33 Ab) not as robust as Dupi in asthma control, also no robustMiljenko Zuanic-June 21
2730Was I wrong on ADVM? Short interest triple in last few months? Who is wrong and Miljenko Zuanic-June 14
2729Eylea PIGF cousin: finance.yahoo.comMiljenko Zuanic-June 7
2728Gotcha, thanks for sharingFelix B-June 6
27275678 is weekly iv, versus every 3 weeks for cemiplimab...so 3 times more frequenMiljenko Zuanic-June 4
2726why not attractive? I am not familiar with oncologyFelix B-June 4
2725Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Miljenko Zuanic-June 4
2724A very interesting question and wondered that myself. 10 point scale--line drawkeokalani'nui-May 24
2723How much mild-to-moderate AD overlap with moderate-to-severe AD?Miljenko Zuanic-May 23
2722FWIW CARA response to Q whether korsuva might have a hard time in AD against bikeokalani'nui-May 23
2721Today I sold my ADVM position. Sound to me that REGN is not much interested abouMiljenko Zuanic-May 20
2720<I continue to be cautious optimistic with ADVM AAV program.> At this poiMiljenko Zuanic-May 17
2719<New data at ASCO include more than double the patients previously reported; Miljenko Zuanic-May 16
27181Q-2019 looks like *disaster*! Is't like that???? I continue to believe thaMiljenko Zuanic-May 8
2717Thoughts on earnings?Felix B-May 7
2716SNY 1Q: sanofi.com @e= 1.14$, Dupi US 1Q sale were $303m (ex-US = $72m), bit loMiljenko Zuanic-April 26
2715Better to spend that profit on stronger Eylea future marketing, they will need iMiljenko Zuanic-April 25
2714Eylea profits will enable Bayer to pay legal settlements and judgments for RoundDewDiligence_on_SI-April 25
2713From Bayer 1Q results ( www.bayer.com/quarterly-release), Eylea ex-US sale are Miljenko Zuanic-April 25
2712Lucentis 1Q ex-US sale were $533M. Not bad....Miljenko Zuanic-April 24
2711Ya I can't think of anything unique about their Ab that would avoid these siFelix B-April 24
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):